GlassScriptPhysician profile
Derek B Lauritzen
NPI 1841348166
$975.89
in general payments reported to CMS, 2019-2025
12 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.19 · 2021: $15.08 · 2022: $512 · 2023: $111 · 2024: $114 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $399.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $308.23 | 2019-2023 | Vabysmo |
| Alcon Vision LLC | $226.13 | 2022-2024 | Clareon, Argos |
| Ani Pharmaceuticals, INC. | $84.38 | 2025 | Iluvien, Yutiq |
| Alimera Sciences, INC. | $62.87 | 2023-2024 | Iluvien, Yutiq |
| Eyepoint US, INC. | $59.76 | 2022 | |
| Astellas Pharma US INC | $57.15 | 2025 | Izervay |
| Nova Eye, INC. | $44.01 | 2024 | |
| Allergan, INC. | $39.48 | 2019-2021 | |
| Harrow Eye, LLC | $33.69 | 2025 | Iheezo |
| Carl Zeiss Meditec USA, INC. | $25.70 | 2024 | Iolmaster 700 |
| Glaukos Corporation | $20.42 | 2023 | |
| Abbvie INC. | $14.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Lauritzen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.